Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds BTIG Downgrades OncoSec Medical to Neutral

BTIG Downgrades OncoSec Medical to Neutral

BTIG analyst Kaveri Pohlman downgrades OncoSec Medical (NASDAQ:ONCS) from Buy to Neutral.

byBenzinga Newsdesk

November 14, 2022

1 minute read

BTIG analyst Kaveri Pohlman downgrades OncoSec Medical (NASDAQ:ONCS) from Buy to Neutral.

J&J’s Tentative $700M Agreement To Resolve Talc Powder-Related Lawsuits Across US States

By Vandana Singh

January 8, 12:19 PM

Healthcare giant Johnson & Johnson (NYSE: JNJ) has reached a tentative agreement to pay approximately $700 million to settle an investigation

JNJ

Vera Bradley Shares Fall On Q2 Revenue Miss, FY23 Outlook Cut

By Shivani Kumaresan

August 31, 10:01 AM

Vera Bradley Inc (NASDAQ:VRA) reported a second-quarter FY23 sales decline of 11.3% year-on-year to $130.37 million, missing the consensus of $132.51…

VRA

American CEO Spills Secrets From Xi Jinping Meeting: China’s President Gave ‘Tough Answers’ On Everything From Economy To Chips To Taiwan

By Shanthi Rexaline

March 28, 6:47 AM

In a meeting that reportedly lasted one-and-a-half hours, Xi extolled the Chinese economy, according to a CEO who attended the meeting.

MCHI

Analyst Ratings

The Latest Analyst Ratings for Boston Props

By Benzinga Insights

August 25, 2:00 PM

Within the last quarter, Boston Props (NYSE:BXP) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

BXP

BTIG Downgrades OncoSec Medical to Neutral

Related Posts

J&J’s Tentative $700M Agreement To Resolve Talc Powder-Related Lawsuits Across US States

Vera Bradley Shares Fall On Q2 Revenue Miss, FY23 Outlook Cut

American CEO Spills Secrets From Xi Jinping Meeting: China’s President Gave ‘Tough Answers’ On Everything From Economy To Chips To Taiwan

The Latest Analyst Ratings for Boston Props